ArticleNPJ precision oncology2021
Multiomics analysis of serial PARP inhibitor treated metastatic TNBC inform on rational combination therapies.
Article in NPJ precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- TALAVE in Breast Cancer:bioRxiv : the preprint server for biology · 2026Article
- Serial Spatial Transcriptomics Reveal Divergent Routes to Therapy Resistance in Metastatic Breast Cancer.Research square · 2026Article
- TRIPODD Enables Single-Cell Quantification of Therapeutic Efficacy.Molecular pharmaceutics · 2026Article
- CD8+ T cells in the tumor microenvironment modulate the response to endocrine therapy in breast cancer.The Journal of clinical investigation · 2026Article
- Acquired resistance in cancer: towards targeted therapeutic strategies.Nature reviews. Cancer · 2025Review
- Editorial Commentary: Should "heterogeneous response" be considered as new category for assessing treatment response in patients with breast cancer?European journal of nuclear medicine and molecular imaging · 2025Article
- C5aR1 inhibition reprograms tumor associated macrophages and reverses PARP inhibitor resistance in breast cancer.Nature communications · 2024Article
- Article
- The Breast Cancer Proteome and Precision Oncology.Cold Spring Harbor perspectives in medicine · 2023Review
- Combining PARP Inhibition and Immunotherapy in BRCA-Associated Cancers.Cancer treatment and research · 2023Article
- Opportunities and challenges to engineer 3D models of tumor-adaptive immune interactions.Frontiers in immunology · 2023Review
- Mechanisms and Strategies to Overcome PD-1/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer.Cancers · 2022Review
- Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical prospects.Medical oncology (Northwood, London, England) · 2022Review
- Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies.Thrombosis research · 2022Article
- Computational multiplex panel reduction to maximize information retention in breast cancer tissue microarrays.PLoS computational biology · 2022Article
- Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer.Nature reviews. Cancer · 2022Review
- The Human Tumor Atlas Network's beginning steps toward the future of collaborative multi-omic discovery.Cell reports. Medicine · 2022Article
- Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases.Frontiers in oncology · 2022Article
- PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors.Oncoimmunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors at 2 institutions in 1 country.
Funding
Abstract
In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as they emerge under therapeutic stress engendered by poly-ADP-ribose polymerase (PARP) inhibitors (PARPi). In a BRCA-mutant basal breast cancer exceptional long-term survivor, a striking tumor destruction was accompanied by a marked infiltration of immune cells containing CD8 effector cells, consistent with pre-clinical evidence for association between STING mediated immune activation and benefit from PARPi and immunotherapy. Tumor cells in the exceptional responder underwent extensive protein network rewiring in response to PARP inhibition. In contrast, there were minimal changes in the ecosystem of a luminal androgen receptor rapid progressor, likely due to indifference to the effects of PARP inhibition. Together, identification of PARPi-induced emergent changes could be used to select patient specific combination therapies, based on tumor and immune state changes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.